Momenta Pharmaceuticals, Inc.
MNTA
MNTA was delisted on the 30th of September, 2020.
154 hedge funds and large institutions have $1.27B invested in Momenta Pharmaceuticals, Inc. in 2019 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 64 increasing their positions, 47 reducing their positions, and 16 closing their positions.
36% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 47
31% more call options, than puts
Call options by funds: $1.51M | Put options by funds: $1.15M
5% more capital invested
Capital invested by funds: $1.21B → $1.27B (+$66.2M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1% less funds holding
Funds holding: 155 → 154 (-1)
6% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$28.7M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$10.4M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$7.94M |
| 4 |
State of New Jersey Common Pension Fund D
Trenton,
New Jersey
|
+$2.54M |
| 5 |
BlackRock
New York
|
+$2.12M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$6.28M |
| 2 |
Primecap Management
Pasadena,
California
|
-$4.06M |
| 3 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$3.89M |
| 4 |
Renaissance Technologies
New York
|
-$3.86M |
| 5 |
Westfield Capital Management
Boston,
Massachusetts
|
-$3.24M |
MNTA Hedge Fund Activity: Q3 2019 in Review
154 of the 4,561 institutional investors tracked by Wall St. Rank reported a position in Momenta Pharmaceuticals, Inc. (MNTA) for Q3 2019, worth a combined $1.27B — up 5.5% from $1.21B a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of MNTA and 15 opened new positions — a net loss of 1 holder — while 47 trimmed existing stakes and 64 added.
The largest buyer was Point72 Asset Management, adding an estimated $28.7M. The largest seller was Wellington Management Group, cutting an estimated $6.28M.
- 154 institutional investors held Momenta Pharmaceuticals, Inc. (MNTA) as of Q3 2019, down from 155 in Q2 2019.
- Funds reported $1.27B of Momenta Pharmaceuticals, Inc. stock for Q3 2019, up 5.5% quarter-over-quarter.
- 15 funds opened new Momenta Pharmaceuticals, Inc. positions in Q3 2019 and 16 closed out, a net change of -1 holder.
- The largest Momenta Pharmaceuticals, Inc. buyer in Q3 2019 was Point72 Asset Management, an estimated $28.7M added.
- The largest Momenta Pharmaceuticals, Inc. seller in Q3 2019 was Wellington Management Group, an estimated $6.28M sold.
Based on aggregated 13F filings for Q3 2019.